MENU
+Compare
ENTBF
Stock ticker: OTC
AS OF
Jul 24 closing price
Price
$0.09
Change
+$0.02 (+28.57%)
Capitalization
1.02M

ENTBF ENTHEON BIOMEDICAL CORP. Forecast, Technical & Fundamental Analysis

Entheon Biomedical Corp is a biotechnology research and development company committed to treat addiction and substance use disorders... Show more

ENTBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ENTBF with price predictions
Jul 25, 2025

ENTBF saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for ENTBF moved out of overbought territory on July 22, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 50 similar instances where the indicator exited the overbought zone. In of the 50 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTBF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ENTBF broke above its upper Bollinger Band on July 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ENTBF entered a downward trend on July 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 15, 2025. You may want to consider a long position or call options on ENTBF as a result. In of 118 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ENTBF just turned positive on July 10, 2025. Looking at past instances where ENTBF's MACD turned positive, the stock continued to rise in of 67 cases over the following month. The odds of a continued upward trend are .

ENTBF moved above its 50-day moving average on July 24, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ENTBF crossed bullishly above the 50-day moving average on July 17, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.761) is normal, around the industry mean (18.028). P/E Ratio (0.000) is within average values for comparable stocks, (59.593). ENTBF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.512). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (6.392) is also within normal values, averaging (278.844).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ENTBF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ENTBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
999 West Broadway Street
Phone
+1 604 562-3932
Employees
N/A
Web
https://www.entheonbiomedical.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PBH76.880.60
+0.79%
Prestige Consumer Healthcare
ESSA20.61N/A
N/A
ESSA Bancorp
HPQ25.68-0.01
-0.04%
HP
RWT6.04-0.01
-0.17%
Redwood Trust
CNVS5.81-0.16
-2.68%
Cineverse Corp

ENTBF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTBF has been loosely correlated with SER. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTBF jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTBF
1D Price
Change %
ENTBF100%
N/A
SER - ENTBF
35%
Loosely correlated
-2.35%
IMRX - ENTBF
31%
Poorly correlated
+1.50%
XTLB - ENTBF
29%
Poorly correlated
-2.51%
GERN - ENTBF
27%
Poorly correlated
-1.56%
LABFF - ENTBF
20%
Poorly correlated
N/A
More